The expert panel of India's drug regulator, DCGI, has permitted Bharat Biotech to give a third dose of Covaxin to a few volunteers in its clinical trials of the COVID-19 vaccine, sources said.
Bharat Biotech presented amendments to the subject expert committee of the Drugs Controller General of India (DCGI) in the approved Phase 2 clinical trial protocol for administration of booster dose six months after second dose.
"The firm presented amendments in the approved Phase 2 clinical trial protocol for administration of booster dose after six months after second dose. After detailed deliberation, the committee recommended that the firm should conduct the booster dose study only in 6 mcg cohort and also should follow up the subjects at least for six months after the third dose," the SEC said.
Further, Bharat Biotech was asked to present the details of the primary and secondary objectives and various assessments to be carried out in the subjects.
"Accordingly, firm(Bharat Biotech) should submit the revised clinical trial protocol for evaluation," the SEC said in the meeting that took place on March 23.
In the meeting, Bharat Biotech presented amendments in the approved Phase 3 clinical trial protocol for unblinding of subjects on placebo and addition of another cohort in Brazil which the SEC recommended.
"After detailed deliberation, the committee recommended that the firm may unblind the participants of age group of more than 45 years and offer to administer the vaccine free of cost as and when they become eligible for the vaccine in the national program," the SEC said.
Further, the SEC recommended that the firm should submit a detailed revised clinical trial protocol for inclusion of cohorts from Brazil along with the revised statistical calculation for assessing the efficacy of the vaccine.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)